| Trial ID: | L5972 |
| Source ID: | NCT00667732
|
| Associated Drug: |
Exenatide
|
| Title: |
How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics
|
| Acronym: |
MEXELIN
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00667732/results
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: exenatide|DRUG: placebo
|
| Outcome Measures: |
Primary: The Percentage of Intent to Treat Participants Randomized and Treated in Each Arm Who Had Lab-measured A1c <6.5% at 24 Weeks of Treatment, After 24 weeks of randomized treatment | Secondary: The Percentage of Per Protocol Participants Randomized and Treated in Each Arm Who Had Lab-measured A1c <6.5% at 24 Weeks of Treatment, efficacy criteria, 50% of per protocol participants reached A1c target of \<6.5%, After 24 weeks of randomized treatment
|
| Sponsor/Collaborators: |
Sponsor: Oregon Health and Science University | Collaborators: Amylin Pharmaceuticals, LLC.|Eli Lilly and Company
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
41
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2007-03
|
| Completion Date: |
2010-04
|
| Results First Posted: |
2013-02-06
|
| Last Update Posted: |
2013-02-06
|
| Locations: |
Medstar Research Institute, Washington DC, District of Columbia, 20003, United States|Mayo Clinic, Rochester, Minnesota, 55905, United States|Oregon Health and Science University, Portland, Oregon, 97239, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00667732
|
